Explore 3 Stock Ideas & Industry Insights Download Free Report

News

TENAX Therapeutics (NASDAQ: TENX) Outlines LEVEL-2 Strategy After Neutral Primary Endpoint

TENAX Therapeutics, Inc. (NASDAQ: TENX) released a comprehensive LEVEL clinical-trial update showing a 49% reduction in NT-proBNP, while the study’s primary endpoint did not reach statistical significance. The results update covers the company’s levosimendan development program and was made public on September 9, 2026. …

Vinay Lochav | 10 September 2026

Tyra Biosciences (NASDAQ: TYRA) Reports 60 Mg Dabogratinib Dose in Bladder Cancer Filing

Tyra Biosciences, Inc. (NASDAQ: TYRA) identified oral dabogratinib at 60 mg once daily as a potential dose for its planned registrational adjuvant strategy in a bladder cancer population with FGFR3 alterations. SURF302 produced an overall response rate of 79%, or 11 of 14 evaluable …

Vinay Lochav | 10 September 2026

UroGen Pharma (NASDAQ: URGN) General Counsel Sells 1,519 Shares at $42.54

UroGen Pharma Ltd. (NASDAQ: URGN) General Counsel Jason Drew Smith sold 1,519 shares at $42.54 per share on Sep. 8. His share ownership afterward stood at 53,141 shares.

Vinay Lochav | 10 September 2026

UroGen Pharma (NASDAQ: URGN) CMO Exercises Options for 1,667 Shares

UroGen Pharma Ltd. (NASDAQ: URGN) Chief Medical Officer Mark Schoenberg exercised options for 1,667 shares on Sep 7, leaving him with 60,753 shares. The next day, he sold 871 shares at $42.92 per share, after which his reported holding stood at 59,882 shares.

Vinay Lochav | 10 September 2026

ProQR Therapeutics (NASDAQ: PRQR) Starts AX-0811 Study After First Participant Dosed

ProQR Therapeutics N.V. (NASDAQ: PRQR) has dosed the first participant in its AX-0811 clinical study, advancing the RNA editing candidate into testing in healthy volunteers. The study will examine safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers for a potential treatment targeting cholestatic liver diseases, including …

Vinay Lochav | 10 September 2026

Pyxis Oncology (NASDAQ: PYXS) Plans Mid-2027 Phase 3 Trial for MICVO

Pyxis Oncology, Inc. (NASDAQ: PYXS) reported updated Phase 1 results for MICVO that support advancing the drug into a key program after a 36% confirmed objective response rate, or 12 of 33 efficacy-evaluable patients. The study evaluated patients with second-line and beyond recurrent or …

Vinay Lochav | 10 September 2026

QIAGEN N.V. (NYSE: QGEN) Names Jonathan M. Pratt CEO From September 1, 2026

QIAGEN N.V. (NYSE: QGEN) appointed Jonathan M. Pratt as chief executive officer effective September 1, 2026, succeeding Thierry Bernard. Bernard also stepped down from the Managing Board on that date, while QIAGEN reaffirmed its third-quarter and full-year 2026 outlook.

Vinay Lochav | 10 September 2026

Radiopharm Theranostics Posts Positive RAD301 P1 Data (NASDAQ: RADX)

RAD301 Shows Selective Pancreatic Tumor Uptake

Vinay Lochav | 10 September 2026

Satellos Bioscience (NASDAQ: MSLE) Renames SAT-3247 Forazapadin for DMD Development

Satellos Bioscience Inc. (NASDAQ: MSLE) will use forazapadin as the international nonproprietary name for its lead drug candidate, previously known as SAT-3247. The orally administered small molecule is being evaluated in clinical studies for Duchenne muscular dystrophy, while Satellos intends to begin a trial …

Vinay Lochav | 10 September 2026

SERA PROGNOSTICS CEO Sells 20,139 Shares at $2 (NASDAQ: SERA)

SERA PROGNOSTICS, INC. (NASDAQ: SERA) shares held by Chief Executive Officer Lindgardt Zhenya fell by 20,139 at a transaction price of $2 per share. The sale took place on September 8, 2026. The reported sale price was $2 per share.

Vinay Lochav | 10 September 2026
Support

Hi! How can we help you today?

Loading…